Related Experiment Video
Updated: May 17, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
Sense from nonsense: therapies for premature stop codon diseases
Laure Bidou1, Valérie Allamand, Jean-Pierre Rousset
1Université Paris-Sud, Orsay, France.
Abstract:
Ten percent of inherited diseases are caused by premature termination codon (PTC) mutations that lead to degradation of the mRNA template and to the production of a non-functional, truncated polypeptide. In addition, many acquired mutations in cancer introduce similar PTCs. In 1999, proof-of-concept for treating these disorders was obtained in a mouse model of muscular dystrophy, when administration of aminoglycosides restored protein translation by inducing the ribosome to bypass a PTC. Since, many studies have validated this approach, but despite the promise of PTC readthrough therapies, the mechanisms of translation termination remain to be precisely elucidated before even more progress can be made. Here, we review the molecular basis for PTC readthrough in eukaryotes and describe currently available compounds with significant therapeutic potential for treating genetic disorders and cancer.
Insights
Premature termination codon (PTC) mutations cause genetic diseases and cancer. Readthrough therapies can restore protein function by bypassing these PTCs, offering new treatment avenues.
Area of Science:
- Molecular Biology
- Genetics
- Pharmacology
Background:
- Premature termination codon (PTC) mutations account for 10% of inherited diseases and are implicated in cancer.
- These mutations lead to mRNA degradation and truncated, non-functional proteins.
- Aminoglycosides demonstrated proof-of-concept for PTC readthrough in 1999, restoring protein translation.
Purpose of the Study:
- To review the molecular mechanisms underlying PTC readthrough in eukaryotes.
- To discuss compounds with therapeutic potential for genetic disorders and cancer caused by PTCs.
Main Methods:
- Literature review of molecular basis for PTC readthrough.
- Analysis of existing compounds for their PTC readthrough efficacy.
Main Results:
- Established molecular mechanisms of translation termination and PTC readthrough.
- Identified several compounds demonstrating significant therapeutic potential.
Conclusions:
- PTC readthrough therapy holds promise for treating genetic disorders and cancer.
- Further elucidation of translation termination mechanisms is crucial for advancing PTC readthrough therapies.
Related Concept Videos
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Signal Sequences and Sorting Receptors
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life

